Prognostic value of ERBB family mRNA expression in breast carcinomas.
about
Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell linesExpression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patientsIdentification of a three-gene expression signature of poor-prognosis breast carcinomaERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancerFunctional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Targeting of erbB3 receptor to overcome resistance in cancer treatmentNuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specificationThe E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradationReduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.Treatment of vestibular schwannoma cells with ErbB inhibitorsPhase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis.ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancerGene expression profiling of the hedgehog signaling pathway in human meningiomas.Differential Shannon entropy and differential coefficient of variation: alternatives and augmentations to differential expression in the search for disease-related genes.The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.The epidermal growth factor receptor family in breast cancer.Direct association of heat shock protein 20 (HSPB6) with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma: regulation of the PI3K activity.Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arraysDifferential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humansIncreased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cellsPrognostic value of ERBB4 expression in patients with triple negative breast cancerHER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-AnalysisActivated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyNeuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas.Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patientsA splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.Estrogen receptor-positive mammary tumorigenesis in TGFalpha transgenic mice progresses with progesterone receptor loss.The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.ErbB3 is required for ductal morphogenesis in the mouse mammary gland.
P2860
Q24318725-65477EA6-EE1D-48AA-93C1-3D39AFFA3990Q24645597-DC4B8478-7FE3-4E52-B632-6A81671EB77EQ24802692-A7B83828-E923-4555-B06C-F988380B942EQ24810389-9592AABC-60A0-4B63-B3AE-3940C4F7F5D8Q24813543-EF7CB3FE-137C-4376-B7F3-77B7F70EC921Q26864668-7510B98D-D727-4768-97A9-0CFA88722956Q27853060-80435BFD-BCD2-492D-A332-3B69A7A22361Q28511622-F549F874-C4D3-4255-9021-97DAF76D2A5CQ28511737-AE5A674F-CFD5-476C-A53B-234B9CB01F2DQ30419961-B994126F-7B5F-4C93-9D7D-B095376F032AQ30458767-A8CD259B-5731-47C7-B045-75FB20E063C9Q33412770-25E19CBE-DA79-4766-93FF-81BE5A92E613Q33676758-09DAEB1A-BAFE-401B-A3D6-D14E039ADE49Q33832583-0E4E4205-F63D-49BD-BD37-0C7DADEB7C78Q33917957-6CB0E004-8A96-4A27-AE20-28185476F1BAQ33921374-9CA00BD1-F833-4DFD-A121-B3402F7ED61FQ33959137-FDB83F38-61DC-46D4-8FC1-83C8A25F4CC3Q34020239-248FAD2A-B0CA-40A4-897D-DDA4E482696BQ34048265-6BA9DF68-6E41-45F9-8C4E-3905D4305952Q34349389-5BDBBEDE-BBEF-4DE7-8BA4-A21B7C5BC0ACQ34363400-8A46D0DA-0D89-46FA-B360-70B1B34A093AQ35040191-3044EFDE-18FD-4BF3-9560-2D62968C24A9Q35103313-CC001907-5F17-4CA0-A683-E3611559EF27Q35214798-56284EBD-B621-41AD-91F9-D753A55BE0F2Q35558954-C593D990-B888-4EF1-A9DC-76F3F813D053Q35663809-8F22DDC7-DE01-4977-A8C8-F5F52C4287B9Q35758261-16F59C02-EED9-434F-95F4-F478BAA70CCFQ35918911-AA72E6F3-59A8-410A-B370-FA4520EEBCDFQ35933318-DD2AFCD8-2DC2-439B-97F0-DD1528654562Q36106546-A947B66B-1959-473D-90A5-6B76259E64ACQ36223407-D53CF798-C55D-444D-AEA8-A39A63B3F1A0Q36288449-7B4539CA-530D-42F7-85E5-526204AF842AQ36609570-708FA18F-3E2A-4DE5-9DD3-2DF33FA75AC5Q36609982-6A09EA49-E485-4BD3-A129-42074E837B6BQ36643014-EF6A27A2-77EC-45D4-BF40-B1E7E7F23FEAQ36730394-2A697829-2B67-42DA-9BD7-09901A1B95EEQ36983423-C1EF739F-E763-4652-84F7-ACA5CE033B9DQ37006174-A3BB2712-2A93-464D-98AA-405D0678A557Q37010568-8E951A89-6C14-43FA-8820-B49A11D1A573Q37131318-4DDCA7ED-5838-4FD9-B7A3-CF9D84A2EB0C
P2860
Prognostic value of ERBB family mRNA expression in breast carcinomas.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Prognostic value of ERBB family mRNA expression in breast carcinomas.
@en
Prognostic value of ERBB family mRNA expression in breast carcinomas.
@nl
type
label
Prognostic value of ERBB family mRNA expression in breast carcinomas.
@en
Prognostic value of ERBB family mRNA expression in breast carcinomas.
@nl
prefLabel
Prognostic value of ERBB family mRNA expression in breast carcinomas.
@en
Prognostic value of ERBB family mRNA expression in breast carcinomas.
@nl
P2093
P2860
P356
P1476
Prognostic value of ERBB family mRNA expression in breast carcinomas.
@en
P2093
Ivan Bièche
Keltouma Driouch
Michel Vidaud
Peter Onody
Rosette Lidereau
Sengül Tozlu
P2860
P304
P356
10.1002/IJC.11273
P577
2003-09-01T00:00:00Z